- 著者
- 星 昭夫 官沢 文彦 飯郷 正明 榑谷 和男
- 出版者
- The Japanese Cancer Association
- 雑誌
- GANN Japanese Journal of Cancer Research (ISSN:0016450X)
- 巻号頁・発行日
- vol.66, no.5, pp.539-546, 1975-10-31 (Released:2008-10-23)
- 参考文献数
- 12
- 被引用文献数
- 2
Combination effect of antitumor agents, including cyclocytidine and cytosine arabinoside, was evaluated on the conception of pharmacological synergism and not of therapeutic synergism. Ascites sarcoma-180 and L-1210 leukemia were used as tumor systems. In sarcoma-180 system, combinations of cyclophosphamide plus cyclocytidine or cytosine arabinoside by simultaneous administration and cyclocytidine plus Daunorubicin or Vinblastine by alternate administration provided synergism. In L-1210 system, many compounds in combination with cyclocytidine or cytosine arabinoside in both simultaneous and alternate administrations provided synergism. Combination effect of agents was affected by the schedule of drug administration. It was found that the combination effect of drugs in one tumor system cannot be generalized to that in other tumor systems, even though equally effective doses of agents were administered in both tumor systems. Toxicity of cytosine arabinoside in combination with other drugs was affected by the schedule of administration. Compounds which provided synergism in simultaneous administration provided antagonism in alternate one. As a result, it was found that alternate administration of drugs is advantageous for the activity and diminution of toxicity to the host animal.
- 著者
- 星 昭夫 官沢 文彦 榑谷 和男
- 出版者
- The Japanese Cancer Association
- 雑誌
- GANN Japanese Journal of Cancer Research (ISSN:0016450X)
- 巻号頁・発行日
- vol.63, no.3, pp.353-360, 1972-06-30 (Released:2008-10-23)
- 参考文献数
- 12
- 被引用文献数
- 4
The antitumor activity of cyclocytidine was examined in a variety of tumors. Cyclocytidine was active against adenocarcinoma-755, Nakahara-Fukuoka sarcoma, ascites sarcoma-180, Ehrlich ascites carcinoma, L-1210 leukemia, and C-1498 leukemia. Cures (60-day survivors) were observed at 500mg/kg/day×5 or more of the compound in the L-1210 system and therapeutic ratio was as high as 50, though that of other known antitumor agents tested, including 1-β-D-arabinofuranosylcytosine (Ara-c), was less than 12. Therapeutic index of cyclocytidine in the solid and ascites tumors was always greater than that of Ara-c. Cumulative toxicity of cyclocytidine was surprisingly low and LD10 was 790mg/kg/day×5, whereas that of Ara-c was 82mg/kg/day×5. Cyclocytidine appears therefore to have advantages over Ara-c for clinical use.
- 著者
- 星 昭夫 官沢 文彦 榑谷 和男 実吉 峯郎 新井 祥子
- 出版者
- The Japanese Cancer Association
- 雑誌
- GANN Japanese Journal of Cancer Research (ISSN:0016450X)
- 巻号頁・発行日
- vol.62, no.2, pp.145-146, 1971-04-30 (Released:2008-10-23)
- 参考文献数
- 8
- 被引用文献数
- 4
2, 2'-O-Cyclocytidine was active against L-1210 leukemia. Cures were observed at the optimal dose of the compound, though no cures were obtained at any dose of any of the known antitumor agents. The compound was less toxic than 1-β-D-arabinofuranosyl-cytosine and resistant to cytidine deaminase.
- 著者
- 官沢 文彦 星 昭夫 榑谷 和男
- 出版者
- The Japanese Cancer Association
- 雑誌
- GANN Japanese Journal of Cancer Research (ISSN:0016450X)
- 巻号頁・発行日
- vol.65, no.1, pp.55-60, 1974-02-28 (Released:2008-10-23)
- 参考文献数
- 22
- 被引用文献数
- 3
Interaction of antitumor agents in activity and in toxicity was examined separately. Ascites sarcoma-180 and ddN mice were used as the tumor system.Interaction was evaluated on the concept of pharmacological synergism and not of therapeutic synergism. In activity, 18 out of 91 combinations provided synergism and most of them contained alkylating agents and antibiotics. Antitumor agents were therefore classified into two groups from the point of drug interaction. Synergism was observed in combinations of agents in Group I, alkylating agents, antibiotics, and alkaloids. In combination of agents in Group II (antimetabolites and others), additive action was observed. As a result, 18, 65, and 8 combinations provided synergism, additive action, and antagonism, respectively.On the other hand, in toxicity, 13, 27, and 38 out of 78 combinations provided synergism, additive action, and antagonism, respectively. The combination that provided synergism in activity and antagonism in toxicity were 8 out of 91 combinations tested. In general, fortunately, combinations of antitumor agents were more than additive in activity and less than additive in toxicity.